RNA editing: emerging from CRISPR’s shadow
Bio Pharma Dive
OCTOBER 22, 2024
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
Moderna founder launches new biotech, looking to cure diseases through 'endless RNA'
Bio Pharma Dive
MAY 10, 2021
Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines.
RNA 
352
352 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Moderna founder unveils new drug company focused on a different kind of RNA
Bio Pharma Dive
NOVEMBER 9, 2021
The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.
RNA 359
359 
Orna, a circular RNA specialist, acquires a buzzy startup
Bio Pharma Dive
MAY 23, 2024
After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.
RNA 301
301 
Next-generation RNA technologies: making longer-lasting drugs with a broader reach
Bio Pharma Dive
AUGUST 23, 2022
At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.
RNA 335
335 
Roche bets on Ionis RNA medicines with neuroscience deal
Bio Pharma Dive
SEPTEMBER 27, 2023
The Swiss drugmaker is restocking its pipeline by buying into preclinical Ionis medicines for Alzheimer’s and Huntington’s diseases.
Medicine 300
300 
As Arrowhead falters, lungs remain a tough target for RNA drugs
Bio Pharma Dive
JULY 6, 2021
The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs.
RNA 307
307 
Venture capital pours more money into RNA medicines with the launch of Replicate
Bio Pharma Dive
SEPTEMBER 8, 2021
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.
RNA 272
272 
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine
Bio Pharma Dive
JUNE 25, 2024
The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.
Medicine 293
293 
Biotech startup Airna raises $60M for RNA editing medicines
Bio Pharma Dive
JULY 31, 2024
Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.
RNA 293
293 
New UK intracellular drug delivery centre to support RNA development
Pharmaceutical Technology
JUNE 1, 2023
A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. The funding is being provided under the agency’s Transforming Medicines Manufacturing programme.
Drug Delivery 242
242 
Lilly and ProQR to expand genetic medicine development agreement
Pharmaceutical Technology
DECEMBER 23, 2022
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.
Genetics 328
328 
AstraZeneca gives up on Ionis’ RNA drug for heart disease
Bio Pharma Dive
SEPTEMBER 23, 2022
The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing.
RNA 317
317 
Moderna reports ‘encouraging’ early data for one of its rare disease medicines
Bio Pharma Dive
MAY 19, 2023
The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.
RNA 300
300 
Wave readies clinical testing for first RNA editing therapy
Bio Pharma Dive
SEPTEMBER 5, 2023
The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.
RNA 184
184 
Orbital raises $270m investment for advancement of RNA medicines
Pharmaceutical Technology
APRIL 27, 2023
Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.
RNA 130
130 
The critical role of comprehensive RNA sequencing in liquid biopsy for biomarker discovery and clinical trials
Bio Pharma Dive
JUNE 17, 2024
Elevate precision medicine: dose optimization and immune monitoring through advanced liquid biopsies.
Clinical Trials 274
274 
Biology opens up new frontiers in medicine to cure genetic diseases: Kiran Mazumdar Shaw
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 17, 2024
Biology is opening up new frontiers in medicine. We are witnessing a revolution in healthcare, driven by advances in genetics, Omics, RNA and CRISPR gene-editing technology, to deliver precision and personalised medicine, said Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics.
Genetic Disease 189
189 
Novartis buys a preclinical biotech and its RNA drug technology
Bio Pharma Dive
JULY 17, 2023
For $500 million, Novartis will acquire DTx Pharma and its preclinical neurological disease drugs, marking the Swiss company’s latest investment in gene-silencing medicines.
Gene Silencing 246
246 
ReNAgade Therapeutics enters RNA therapy arena with $300m
Pharmaceutical Technology
MAY 23, 2023
ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”
RNA 147
147 
Vertex tiptoes further into Duchenne research with Tevard deal
Bio Pharma Dive
FEBRUARY 28, 2023
An alliance with the startup brings Vertex an RNA-based medicine for the disease, adding to a portfolio that already includes a gene editing treatment.
Gene Editing 274
274 
CSL says drug for rare swelling disorder succeeds in late-stage study
Bio Pharma Dive
AUGUST 18, 2022
The company plans to soon seek approval of a once-monthly preventive drug for hereditary angioedema, a disease other drugmakers are targeting with gene editing and RNA medicines.
Gene Editing 273
273 
Beyond Covid-19: the disruptive potential of RNA-based therapeutics
Pharmaceutical Technology
MARCH 1, 2023
Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.
RNA 147
147 
Eli Lilly adds ALS drug prospect with QurAlis deal
Bio Pharma Dive
JUNE 3, 2024
The alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to develop other, similar medicines.
RNA 218
218 
State of Play: A closer look at hotspots of emerging biotech research
Bio Pharma Dive
NOVEMBER 29, 2022
In this continuing series, BioPharma Dive examines new areas of biotech investment and startup activity, such as next-generation RNA medicines, TYK2 inhibitors and in vivo CAR-T.
In-Vivo 240
240 
Ochre Bio raises funds to develop RNA therapies for liver diseases
Pharmaceutical Technology
OCTOBER 11, 2022
Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.
RNA 130
130 
GSK dives into NASH, RNA interference with Arrowhead deal
Bio Pharma Dive
NOVEMBER 23, 2021
GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people and which has proven to be a tough target for drugmakers.
RNA 190
190 
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Bio Pharma Dive
NOVEMBER 12, 2024
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.
RNA 167
167 
Merck and Orna partner for RNA technology-based vaccines and therapies
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.
RNA 147
147 
FDA denies expanded approval for Alnylam RNA drug
Bio Pharma Dive
OCTOBER 9, 2023
The agency rejected Alnylam’s application for approval of its medicine patisiran in people with a rare heart condition, setting back the company’s plans.
RNA 167
167 
CSL, Arcturus get first approval for self-assembling RNA jab
pharmaphorum
NOVEMBER 29, 2023
Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower dose.
RNA 115
115 
Eli Lilly Pursues RNA Editing in New Partnership with ProQR
XTalks
SEPTEMBER 13, 2021
With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.
RNA 105
105 
Arrowhead reports positive data from liver drug, but company’s shares slide
Bio Pharma Dive
JANUARY 9, 2023
The biotech and partner Takeda also announced a Phase 3 study of the RNA medicine that is longer than anticipated, pushing out analysts’ timelines.
RNA 196
196 
Alnylam becomes new partner in the Medicines Manufacturing Innovation Centre
Pharma Times
OCTOBER 7, 2021
Leading RNA intereference (RNAi) therapeutics company, Alnylam, has been welcomed as the latest partner in the Medicines Manufacturing Innovation Centre, to transform the manufacturing process of oligonucleotide therapies.
Manufacturing 116
116 
Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’
Bio Pharma Dive
MARCH 14, 2023
The company’s name comes from its goal of developing drugs that only “switch” on in target cells, potentially enabling more precise therapies.
RNA 130
130 
Pushing Beyond Gene Editing Limits with Programmable RNA Medicines
BioSpace
JUNE 12, 2022
Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss.
Gene Editing 71
71 
How RNA-Based Pesticides Can Improve Pest Control
XTalks
NOVEMBER 9, 2021
Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.
RNA 98
98 
ReviR Therapeutics partners with Asieris to develop new oncology therapies
Pharmaceutical Technology
FEBRUARY 9, 2023
The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.
Development 241
241 
ReNAgade Launches with $300M to More Easily Deliver RNA Medicines
BioSpace
MAY 22, 2023
ReNAgade Launches with $300M to More Easily Deliver RNA Medicines 5/23/2023
RNA 70
70 
Locanabio’s RNA-Targeting Gene Therapy May Offer Durable Response for DM1 Patients
BioSpace
SEPTEMBER 22, 2020
RNA-binding proteins are emerging as the next generation of molecular medicine.
RNA 96
96 
Deep Genomics is Rewriting RNA for Powerful Therapeutics with $180M Series C
BioSpace
JULY 27, 2021
"For the first time in history, medicine has become information." That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.
RNA 96
96 
Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class
pharmaphorum
MAY 11, 2021
Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.
RNA 98
98 
Let's personalize your content